UBS O'Connor
RVLP

UBS O'Connor’s RVL Pharmaceuticals plc Ordinary Shares RVLP Stock Holding History

UBS O'Connor’s Portfolio RVLP Stock Details RVLP Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2023
Q3 		– Sell
-254,736
Closed -$143K – 664
2023
Q2 		$143K Sell
254,736
-21,692
-8% -$19.1K ﹤0.01% 485
2023
Q1 		$315K Hold
276,428
– – 0.01% 494
2022
Q4 		$310K Hold
276,428
– – 0.01% 638
2022
Q3 		$580K Buy
+276,428
New +$537K 0.01% 801

Other funds holding RVLP

Athyrium Capital Management
Athyrium Capital Management New York $8.69M AUM 34.58% 1-Year Est. Return
Renaissance Technologies
Renaissance Technologies New York $72.6B AUM 54.88% 1-Year Est. Return
Blackstone Inc
Blackstone Inc New York $39B AUM 18.55% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.92T AUM 36.1% 1-Year Est. Return
Millennium Management
Millennium Management New York $276B AUM 44.8% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $3.44T AUM 36.12% 1-Year Est. Return
Raymond James Financial Services Advisors
Raymond James Financial Services Advisors St. Petersburg, Florida $75.1B AUM 31.89% 1-Year Est. Return
Titleist Asset Management
Titleist Asset Management San Antonio, Texas $1.55B AUM 13.34% 1-Year Est. Return

UBS O'Connor's RVLP Position: Q3 2023 in Review

UBS O'Connor sold out of RVL Pharmaceuticals plc Ordinary Shares (RVLP) in Q3 2023, closing a stake of 254,736 shares — an estimated $143K sold.

UBS O'Connor first reported a position in RVLP in Q3 2022 and held it in 4 quarters. The position peaked at $580K in Q3 2022. 32 funds tracked by Wall St. Rank hold RVLP as of Q3 2023.

  • UBS O'Connor reported no remaining RVL Pharmaceuticals plc Ordinary Shares position as of Q3 2023 after selling out during the quarter.
  • UBS O'Connor sold 254,736 RVL Pharmaceuticals plc Ordinary Shares shares in Q3 2023, an estimated $143K.
  • UBS O'Connor first reported a position in RVL Pharmaceuticals plc Ordinary Shares in Q3 2022 and held it in 4 quarters.
  • UBS O'Connor's RVL Pharmaceuticals plc Ordinary Shares position peaked at $580K in Q3 2022.
  • 32 funds tracked by Wall St. Rank held RVL Pharmaceuticals plc Ordinary Shares as of Q3 2023.

Based on UBS O'Connor's 13F filing for Q3 2023, filed 14 Nov 2023.